Surface Oncology, Inc. (SURF)
Stock Price:
$8.69 USD
-0.88 (-9.20%)
Updated Oct 26, 2020 12:51 PM EDT - Market open
Key Info
| Market Cap |
346.78M |
| Revenue (ttm) |
39.38M |
| Net Income (ttm) |
-25.07M |
| Shares Out |
39.91M |
| EPS (ttm) |
-0.86 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$8.69 |
| Previous Close |
$9.57 |
| Change ($) |
-0.88 |
| Change (%) |
-9.20% |
| Day's Open |
9.50 |
| Day's Range |
8.68 - 9.56 |
| Day's Volume |
373,669 |
| 52-Week Range |
1.36 - 10.25 |
More Stats
| Market Cap |
346.78M |
| Enterprise Value |
282.63M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
39.91M |
| Float |
31.43M |
| EPS (basic) |
-0.82 |
| EPS (diluted) |
-0.86 |
| FCF / Share |
-1.80 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
567,365 |
| Short Ratio |
0.62 |
| Short % of Float |
1.81% |
| Beta |
2.39 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
8.81 |
| PB Ratio |
3.61 |
| Revenue |
39.38M |
| Operating Income |
-25.91M |
| Net Income |
-25.07M |
| Free Cash Flow |
-60.20M |
| Net Cash |
64.16M |
| Net Cash / Share |
1.61 |
| Gross Margin |
-93.35% |
| Operating Margin |
-65.81% |
| Profit Margin |
-63.70% |
| FCF Margin |
-152.90% |
| ROA |
-9.99% |
| ROE |
-27.55% |
| ROIC |
-25.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
5 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.80*
(24.28% upside)
Low
9.00
Current: $8.69
High
12.00
Target: 10.80
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 15.36 | 59.42 | 12.83 | 6.63 |
| Revenue Growth | -74.15% | 363.25% | 93.4% | - |
| Gross Profit | 15.36 | 59.42 | 12.83 | 6.63 |
| Operating Income | -57.37 | -9.15 | -45.99 | -18.00 |
| Net Income | -54.79 | -6.60 | -45.38 | -17.45 |
| Shares Outstanding | 27.85 | 19.99 | 2.47 | 2.39 |
| Earnings Per Share | -1.97 | -0.33 | -18.35 | -7.31 |
| Operating Cash Flow | -60.14 | -13.22 | -12.42 | 41.41 |
| Capital Expenditures | -1.54 | -2.02 | -1.97 | -0.84 |
| Free Cash Flow | -61.68 | -15.24 | -14.40 | 40.58 |
| Cash & Equivalents | 107 | 160 | 64.39 | 80.24 |
| Total Debt | 25.04 | - | - | - |
| Net Cash / Debt | 81.72 | 160 | 64.39 | 80.24 |
| Assets | 132 | 174 | 81.45 | 98.14 |
| Liabilities | 75.03 | 71.20 | 100 | 76.57 |
| Book Value | 56.67 | 103 | -67.31 | -26.91 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Surface Oncology, Inc. |
| Country |
United States |
| Employees |
49 |
| CEO |
J. Jeffrey Goater |
Stock Information
| Ticker Symbol |
SURF |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SURF |
| IPO Date |
April 19, 2018 |
Description
Surface Oncology, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDAÂ (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.